Z. Nogareda Seoane , M.C. Mallón Araújo , A. Calatayud Cubes , C. Barberán Corral , Y. Domínguez Novoa , A. Cousillas Castiñeira , N. Martínez Lago , J.M. de Matías Leralta , V. Pubul Nuñez
{"title":"神经内分泌肿瘤的功能成像：使用[68Ga]Ga-DOTA-TOC和[18F]FDG PET/CT评估分子异质性。","authors":"Z. Nogareda Seoane , M.C. Mallón Araújo , A. Calatayud Cubes , C. Barberán Corral , Y. Domínguez Novoa , A. Cousillas Castiñeira , N. Martínez Lago , J.M. de Matías Leralta , V. Pubul Nuñez","doi":"10.1016/j.remnie.2024.500011","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The aim of the study was evaluate the diagnostic performance of [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG PET/CT in patients with histologically proven neuroendocrine tumors (NETs), as well as the correlation of the visualized findings with the tumor grade.</p></div><div><h3>Material and methods</h3><p>We included 50 patients with NETs who underwent both [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG PET/TC. The pooled sensitivity of both scans was compared, as well as [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG for each tumor grade (grade 1/G1, grade 2/G2 and grade 3/G3). Also, the sensitivity of [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG as a function of the continuous variable Ki-67 was investigated. Finally, the number of lesions detected by both PET radiopharmaceuticals for each tumor grade was compared.</p></div><div><h3>Results</h3><p>The pooled sensitivity of both PET/CT (96%) was higher than [68Ga]Ga-DOTA-TOC (84%) and [<sup>18</sup>F]FDG (44%) separately, with statistically significant differences. The sensitivity of [<sup>68</sup>Ga]Ga-DOTA-TOC was higher than [<sup>18</sup>F]FDG in both G1 (p = 0.004) and G2 (p < 0.001). In G3 the performance of both scans detected disease in 100% of this subgroup. The sensitivity of [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG PET/CT correlated significantly with the Ki-67 proliferative index. In G2 patients the number of lesions detected with [<sup>68</sup>Ga]Ga-DOTA-TOC was higher than [<sup>18</sup>F]FDG.</p></div><div><h3>Conclusions</h3><p>The performance of both PET/CT, particularly in G2 and G3, demonstrates the molecular heterogeneity of metastatic NETs and contributes to the selection of a more appropriate treatment, particularly in those high-grade patients who may benefit from radionuclide therapy (PRRT).</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"43 3","pages":"Article 500011"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT\",\"authors\":\"Z. Nogareda Seoane , M.C. Mallón Araújo , A. Calatayud Cubes , C. Barberán Corral , Y. Domínguez Novoa , A. Cousillas Castiñeira , N. Martínez Lago , J.M. de Matías Leralta , V. Pubul Nuñez\",\"doi\":\"10.1016/j.remnie.2024.500011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>The aim of the study was evaluate the diagnostic performance of [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG PET/CT in patients with histologically proven neuroendocrine tumors (NETs), as well as the correlation of the visualized findings with the tumor grade.</p></div><div><h3>Material and methods</h3><p>We included 50 patients with NETs who underwent both [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG PET/TC. The pooled sensitivity of both scans was compared, as well as [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG for each tumor grade (grade 1/G1, grade 2/G2 and grade 3/G3). Also, the sensitivity of [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG as a function of the continuous variable Ki-67 was investigated. Finally, the number of lesions detected by both PET radiopharmaceuticals for each tumor grade was compared.</p></div><div><h3>Results</h3><p>The pooled sensitivity of both PET/CT (96%) was higher than [68Ga]Ga-DOTA-TOC (84%) and [<sup>18</sup>F]FDG (44%) separately, with statistically significant differences. The sensitivity of [<sup>68</sup>Ga]Ga-DOTA-TOC was higher than [<sup>18</sup>F]FDG in both G1 (p = 0.004) and G2 (p < 0.001). In G3 the performance of both scans detected disease in 100% of this subgroup. The sensitivity of [<sup>68</sup>Ga]Ga-DOTA-TOC and [<sup>18</sup>F]FDG PET/CT correlated significantly with the Ki-67 proliferative index. In G2 patients the number of lesions detected with [<sup>68</sup>Ga]Ga-DOTA-TOC was higher than [<sup>18</sup>F]FDG.</p></div><div><h3>Conclusions</h3><p>The performance of both PET/CT, particularly in G2 and G3, demonstrates the molecular heterogeneity of metastatic NETs and contributes to the selection of a more appropriate treatment, particularly in those high-grade patients who may benefit from radionuclide therapy (PRRT).</p></div>\",\"PeriodicalId\":94197,\"journal\":{\"name\":\"Revista espanola de medicina nuclear e imagen molecular\",\"volume\":\"43 3\",\"pages\":\"Article 500011\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista espanola de medicina nuclear e imagen molecular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2253808924000235\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de medicina nuclear e imagen molecular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2253808924000235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT
Objective
The aim of the study was evaluate the diagnostic performance of [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT in patients with histologically proven neuroendocrine tumors (NETs), as well as the correlation of the visualized findings with the tumor grade.
Material and methods
We included 50 patients with NETs who underwent both [68Ga]Ga-DOTA-TOC and [18F]FDG PET/TC. The pooled sensitivity of both scans was compared, as well as [68Ga]Ga-DOTA-TOC and [18F]FDG for each tumor grade (grade 1/G1, grade 2/G2 and grade 3/G3). Also, the sensitivity of [68Ga]Ga-DOTA-TOC and [18F]FDG as a function of the continuous variable Ki-67 was investigated. Finally, the number of lesions detected by both PET radiopharmaceuticals for each tumor grade was compared.
Results
The pooled sensitivity of both PET/CT (96%) was higher than [68Ga]Ga-DOTA-TOC (84%) and [18F]FDG (44%) separately, with statistically significant differences. The sensitivity of [68Ga]Ga-DOTA-TOC was higher than [18F]FDG in both G1 (p = 0.004) and G2 (p < 0.001). In G3 the performance of both scans detected disease in 100% of this subgroup. The sensitivity of [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT correlated significantly with the Ki-67 proliferative index. In G2 patients the number of lesions detected with [68Ga]Ga-DOTA-TOC was higher than [18F]FDG.
Conclusions
The performance of both PET/CT, particularly in G2 and G3, demonstrates the molecular heterogeneity of metastatic NETs and contributes to the selection of a more appropriate treatment, particularly in those high-grade patients who may benefit from radionuclide therapy (PRRT).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
